Bon Natural Life Limited Ordinary Shares - BON STOCK NEWS

Bon Natural Life Limited (Nasdaq: BON) reported a 17.3% revenue increase for the fiscal year 2022, reaching $29.9 million. The net income rose by 35.4% to $6.2 million, translating to $0.74 per diluted share. The company's gross profit saw a 32.5% rise to $9.4 million, and gross margin improved to 31.5%. Significant growth was noted in bioactive food ingredients, with revenue and gross profits increasing by 48.5% and 61.4%, respectively. Management anticipates further growth with the upcoming Yumen Plant expected to boost annual revenues by 150% once operational. The full results were discussed in a live webinar on February 10, 2023.

Bon Natural Life Limited (Nasdaq: BON) is set to release its FY2022 earnings report before market opens on February 10, 2023. The earnings will cover the fiscal year ending September 30, 2021. Alongside the release, the company will conduct an investor conference call at 9:00 a.m. EST, featuring key executives including CEO Richard Hu and CFO Zhenchao Li. The call will be available via pre-registration and can also be accessed later as an archived recording. Bon Natural focuses on producing bio-ingredient solutions for the health and personal care sectors, including plant extracts and bioactive food products.

Bon Natural Life Limited (Nasdaq: BON) announced a delay in the initial production target for its new Yumen Plant from Q4 2022 to May 2023. The construction, which began in July 2021, faced challenges due to strict COVID-19 protocols, logistic disruptions, and labor shortages. Despite completing the building structure in May 2022, interior outfitting and equipment installation were hindered. CEO Richard Hu expressed confidence in the plant's potential to enhance production of fragrance compounds and bioactive food ingredients amid ongoing pandemic-related uncertainties.

Bon Natural Life Limited (Nasdaq: BON) reported a 17.0% revenue increase to US$13.7 million for 1H-2022. Gross profit rose 19.6% to US$4.0 million, with a gross margin of 29.5%. Notably, bioactive food ingredient sales surged 171.8%, while health supplements fell 28.5%. Net income improved by 10.2% to US$2.5 million, although diluted EPS decreased to $0.30 from $0.40 year-over-year. The company is expanding production capabilities with the Yumen plant, set to boost capacity by 200%.

Bon Natural Life Limited (Nasdaq: BON) will release its half-year earnings for the period ending March 31, 2022, on August 1, 2022, before market open. The company also plans to host an investor conference call at 9:00 a.m. EST on the same day, featuring key executives. The call will be accessible via pre-registration or through provided dial-in options. BON specializes in bio-ingredient solutions for personal care and health products. For further insights, investors can access the webcast through the company's investor website.

Bon Natural Life Limited (Nasdaq: BON) announced the appointment of Jeffrey Guzy as an independent Director and Chair of the Audit Committee, effective June 28, 2022. This follows the resignation of Christopher Constable from the Board, which was not due to any disputes. Jeffrey Guzy brings extensive experience from major firms like Loral Space and IBM, enhancing BON's governance and financial oversight. CEO Yongwei Hu expressed optimism about Guzy's contribution to the company's growth in the natural health and personal care sectors.

Bon Natural Life Limited (Nasdaq: BON) has launched a new proprietary cruciferous vegetable-based probiotic powder drink aimed at inhibiting Helicobacter pylori proliferation and enhancing digestive health. The product marks the first in its health supplement series, tapping into a growing market for multifunctional probiotics, particularly post-COVID-19. With H. pylori infections prevalent in China, where nearly 55.8% of the population was affected as of 2017, and the probiotics market expanding significantly, this initiative presents considerable growth potential for BON.

Bon Natural Life Limited (Nasdaq: BON) announced significant progress with its Yumen Plant, expected to commence production by September 2022. The facility will enhance production capacity for fragrance compounds and bioactive food ingredients by 200%, with potential annual revenue growth of 150%. The recent removal of the VIE structure allows shareholders direct ownership of operational entities. Positive feedback was noted for newly developed natural personal care products and an expansion of distribution channels amidst the challenges posed by the COVID-19 pandemic.

Bon Natural Life Limited (Nasdaq: BON) announced the development of new nutraceutical compounds, Glucoraphanin (GF) and Sulforaphane (SFN), extracted from cruciferous vegetables. These compounds are believed to support immunity and other health functions, showing potential in inhibiting SARS-CoV-2 infections, as per a study from John Hopkins University. The company plans to launch GF and SFN-based consumer products within six months, including immune boosters, digestive health supplements, and weight loss products. This marks a significant milestone in BON's strategy to expand its product offerings.